Citations

Clear

4847 citation(s) found for "Yu, Eric".

Outcomes of Primary Reverse Shoulder Arthroplasty for Dislocation Arthropathy
Sperling, John W. , Cofield, Robert H. , Chalmers, Brian P. , Wagner, Eric R. , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Shoulder and Elbow Arthroplasty | July 14, 2017 | Volume: 1 | Issue: No issue available | Pages: No page available

10.1177/2471549217717165 Get It

Background Proper soft tissue balance is paramount to maintaining stability and a functional arc of motion in shoulder arthroplasty but is impaired in patients with prior glenohumeral (GH) dislocations. The purpose of this study was to determine the clinical outcomes, revisions, and complications of reverse shoulder arthroplasty (RSA) in patients with a history of glenohumeral dislocation. Methods Twenty-four patients with a history of GH dislocations that developed arthropathy underwent primary RSA from 2007 to 2013 were retrospectively reviewed. Mean follow-up was 3.3 years (2–7 years). Mean age was 70 years. Eight patients (33%) and 7 patients (29%) had complete or partial subscapularis deficiency, respectively. Results Twenty-two patients (92%) had little to no pain at final follow-up. Mean shoulder elevation improved from 48° to 120° ( P < .001) and mean external rotation increased from 13.2° to 48° ( P < .001). There were trends toward less complete pain relief and poorer motion in those with complete subscapularis deficiency. None of the patients experienced a postoperative dislocation or evidence of glenoid loosening at final radiographic follow-up, but 1 patient (4.2%) underwent early revision to a hemiarthroplasty for glenoid loosening. Conclusion RSA provides patients with prior glenohumeral dislocations a stable, pain-free arc of motion. Postoperative instability was not identified as a major failure mode at short-term follow-up. Complete subscapularis deficiency is a risk factor for poorer clinical outcome.
Is Intravenous Administration of Iodixanol Associated with Increased Risk of Acute Kidney Injury, Dialysis, or Mortality? A Propensity Score–adjusted Study
McDonald, Robert J. , Williamson, Eric E. , Kallmes, David F. , McDonald, Jennifer S.

Mayo Clinic

Radiology | July 14, 2017 | Volume: 285 | Issue: 2 | Pages: 414-424

10.1148/radiol.2017161573 | PMID 28708022 Get It

Comparable Rates of Glucocorticoid‐Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population
Shbeeb, Izzat, Challah, Divya, Raheel, Shafay , Crowson, Cynthia S. , Matteson, Eric L.

Mayo Clinic

Arthritis Care & Research | July 13, 2017 | Volume: 70 | Issue: 4 | Pages: 643-647

10.1002/acr.23320 | PMID 28704600 Get It

ObjectiveTo investigate the use of glucocorticoids (GCs) and related adverse events (AEs) in a long‐term, geographically defined cohort of patients with polymyalgia rheumatica (PMR).MethodsUsing a population‐based inception cohort, details of GC therapy were abstracted from medical records of all patients diagnosed with PMR in 2000–2014. Age‐ and sex‐matched comparators without PMR were identified from the same underlying population. Cumulative and daily dosage of GC, rate of disease relapse, occurrence of GC‐related AEs, and rate of GC discontinuation were analyzed.ResultsThe study included 359 patients with PMR and 359 comparators. The median time to taper below 5 mg/day for 6 months was 1.44 years (95% confidence interval [95% CI] 1.36–1.62), while the median time to permanent discontinuation was 5.95 years (95% CI 3.37–8.88). The mean ± SD cumulative dose of GC at 2 and 5 years was 4.0 ± 3.5 grams and 6.3 ± 9.8 grams, respectively. The mean ± SD daily dose of GC at 2 and 5 years was 6.1 ± 7.6 mg/day and 7.2 ± 9.5 mg/day, respectively. There were no differences in rates of AEs between patients with PMR and comparators for diabetes mellitus, hypertension, hyperlipidemia, or hip, vertebral, or Colles fractures (P > 0.2 for all). Cataracts were more common in patients with PMR than comparators (hazard ratio 1.72 [95% CI 1.23–2.41]).ConclusionRelapse rates in PMR are highest in the early stages of therapy. Despite often protracted therapy, with the exception of cataracts, the rates of studied morbidities linked to GC are not more common in PMR than comparators.
Single‐center experience of antifungal prophylaxis for coccidioidomycosis in heart transplant recipients within an endemic area
Lohrmann, Graham , Vucicevic, D., Lawrence, Romy, Steidley, D. Eric , Scott, Robert L. , Kusne, Shimon , Blair, Janis E. , Lohrmann, Graham M, Vucicevic, Darko

Mayo Clinic

Transplant Infectious Disease | July 11, 2017 | Volume: 19 | Issue: 5 | Pages: No page available

10.1111/tid.12744 | PMID 28695649 Get It

AbstractIn endemic regions, coccidioidomycosis causes substantial morbidity and mortality for patients receiving solid organ transplants. We aimed to demonstrate the effect of antifungal coccidioidal prophylaxis in heart transplant (HT) recipients. We retrospectively reviewed the electronic health records of all patients who received HTs between October 19, 2005, and December 13, 2014. We collected information regarding antifungal regimens and determined whether patients subsequently developed infections. Our 174‐person cohort all received antifungal prophylaxis for at least 6 months (mean follow‐up, 53.8 months). One proven and one probable coccidioidal infection (each, 0.6%) occurred during the study period. The incidence of coccidioidomycosis was 0.6% at 1 year and 2.3% at 5 years. No cases of proven coccidioidomycosis occurred within 2 years after transplantation. No patients developed disseminated disease, and no sentinel events were attributed to coccidioidomycosis. Both fluconazole and voriconazole were well tolerated. In the absence of intolerance or contraindication, we suggest continuing a universal antifungal prophylactic regimen with fluconazole for at least 6‐12 months in HT recipients residing in a coccidioidomycosis‐endemic area.
NTRK1-3 point mutations in poor prognosis thyroid cancers.
Iñiguez‐Ariza, Nicole M. , Bible, Keith C. , Shridhar, Vijayalakshmi, Smallridge, Robert C., Menefee, Michael E., Hilger, Crystal, Severson, Eric A. , Morris, John C., Chintakuntlawar, Ashish V. , Ryder, Mabel

Mayo Clinic

Journal of Clinical Oncology | July 6, 2017 | Volume: 35 | Issue: 15_suppl | Pages: 6087-6087

10.1200/jco.2017.35.15_suppl.6087 Get It

6087 Background: NTRK1-3 fusions, identified in pediatric radiation-associated thyroid cancers, are low frequency oncogenic drivers that can trigger constitutive activation of TrK1-3 tyrosine kinase domains with responsively heightened downstream signaling through RAS-MAPK, PI3K-AKT, and/or PLCγ-PKC. NTRK point mutations are rare and of largely uninvestigated oncogenic potential, but some appear oncogenic. Methods: Advanced thyroid cancer (TC) patients (pts) requiring systemic therapy at Mayo Clinic sites underwent tumor genetic interrogation using Foundation One analyses with the goal of informing salvage therapeutic strategies. In this IRB-approved study, data from pts with TCs bearing NTRK point mutations were retrospectively analyzed, as this occurrence was unexpected but potentially of prognostic and/or therapeutic relevance. Results: Five of 55 pts (9%) with advanced TCs subject to Foundation One tumor interrogation had NTRK1-3 point mutations (allele frequency, AF, 15-49%); none had fusions. All 5 tumors had microsatellite stability; 4/5 had low tumor mutation burden (2-5 mutations/megabase). NTRK mutations in 3 anaplastic TC (ATC) pts (15% prevalence) were: NTRK3 I749M (AF 15%; overall survival, OS, 15 mos), NTRK1 R744H (AF not available; OS 9.5 mos), and NTRK1 R583H (AF 20.1%; OS > 4.9 mos); NTRK2 S167Y (AF 49%; OS > 51 mos) or NTRK1 R6W (AF 42%; OS > 60 mos) were found in one papillary (PTC) and one Hürthle cell (HCC) TC pt respectively (summary table below). Conclusions: NTRK point mutations, but not fusions, were unexpectedly identified in 9% of assessed advanced TCs - but remarkably in 15% of ATCs. Mutated NTRKs, along with oncogenic p53 and TERT, may contribute to TC progression, especially in ATC, consequent to downstream activation of MAPK and PI3K-AKT pathways. We posit that NTRK point mutations may have therapeutic implications for treatment of refractory disease. [Table: see text]
Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience
Gamez, Mauricio E. , Jeans, Elizabeth B. , Hinni, Michael L., Moore, Eric J. , Young, Geoffrey D., McGee, L.A. , Buras, Matthew , Patel, Samir H. , Moore, Eric, Young, Geoffrey, Ma, Daniel, McGee, Lisa, Daniel, J. , Buras, Matthew R

Mayo Clinic

The Laryngoscope | July 6, 2017 | Volume: 128 | Issue: 2 | Pages: 373-377

10.1002/lary.26725 | PMID 28681992 Get It

Objectives/HypothesisSarcomatoid carcinoma is a rare variant of squamous cell carcinoma of the head and neck. No consensus exists on its management. Our aim was to present our outcomes.Study DesignRetrospective study. Median follow‐up 45 months.MethodsThere were 38 patients with pathologically confirmed sarcomatoid carcinoma of the larynx treated at the Mayo Clinic from 1990 to 2014. Statistical analysis of overall survival (OS), progression‐free survival (PFS), and local control (LC) were conducted using the Kaplan‐Meier method.ResultsThe majority of patients were elderly males (92%) with a smoking history (74%) presenting with early‐stage disease (71%). Surgery alone was the primary treatment in 27 patients (71%). Nine patients (25%) were treated with adjuvant radiation due to initial stage or high‐risk pathologic features. Median radiation dose to the primary/surgical bed was 65 Gy (range, 60.3–75.0 Gy). A total of 15 patients (39%) had tumor recurrence, majority being local (n = 12). Sixty percent (n = 9) had multiple local recurrences. Five‐year OS, PFS, and LC were 63%, 46%, and 72%, respectively. Subgroup analysis by stage I versus higher stages (II–IV) showed an OS of 80% versus 43% (P = .030), PFS of 65% versus 18% (P = .003), and LC of 84% versus 57% (P = .039).ConclusionsSarcomatoid carcinoma of the larynx is rare, and frequently presents at an early stage in older men with history of smoking. Based on our outcomes and patterns of failure, it appears early‐stage tumors are treated appropriately with single‐modality therapy, whereas more advanced tumors require multimodality therapy. Validation in a larger cohort is warranted.Level of Evidence4. Laryngoscope, 128:373–377, 2018
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Cynthia, X. , Bose, Ron , Gao, Feng , Telli, Melinda L. , Kimmick, Gretchen , Russell, Christy , Cobleigh, Melody , Forero, Andres , Anders, Carey K. , Thomas, Shana , Anderson, J. L. , Bumb, Caroline, Banks, Kimberly C. , Bryce, Richard , Lalani, Alshad S. , Pfeifer, John D. , Hayes, Daniel F. , Pegram, Mark D. , Blackwell, Kimberly , Bédard, Philippe L. , Al‐Kateb, Hussam , Freedman, Rachel A. , Winer, Eric P. , Naughton, Michael J. , Goetz, Matthew P. , Tripathy, Debu , Pluard, Timothy , Niravath, Polly Ann , Anderson, Jill, Lanman, Richard B. , Ellis, Matthew J. , Banks, Kimberly C , Gao, Feng , Telli, Melinda L

Mayo Clinic

Clinical Cancer Research | July 5, 2017 | Volume: 23 | Issue: 19 | Pages: 5687-5695

10.1158/1078-0432.ccr-17-0900 | PMID 28679771 Get It

Abstract Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) HER2mut detection. Experimental Design: Tumor tissue positive for HER2mut was required for eligibility. Neratinib was administered 240 mg daily with prophylactic loperamide. ctDNA sequencing was performed retrospectively for 54 patients (14 positive and 40 negative for tumor HER2mut). Results: Nine of 381 tumors (2.4%) sequenced centrally harbored HER2mut (lobular 7.8% vs. ductal 1.6%; P = 0.026). Thirteen additional HER2mut cases were identified locally. Twenty-one of these 22 HER2mut cases were estrogen receptor positive. Sixteen patients [median age 58 (31–74) years and three (2–10) prior metastatic regimens] received neratinib. The CBR was 31% [90% confidence interval (CI), 13%–55%], including one CR, one PR, and three SD ≥24 weeks. Median PFS was 16 (90% CI, 8–31) weeks. Diarrhea (grade 2, 44%; grade 3, 25%) was the most common adverse event. Baseline ctDNA sequencing identified the same HER2mut in 11 of 14 tumor-positive cases (sensitivity, 79%; 90% CI, 53%–94%) and correctly assigned 32 of 32 informative negative cases (specificity, 100%; 90% CI, 91%–100%). In addition, ctDNA HER2mut variant allele frequency decreased in nine of 11 paired samples at week 4, followed by an increase upon progression. Conclusions: Neratinib is active in HER2mut, nonamplified MBC. ctDNA sequencing offers a noninvasive strategy to identify patients with HER2mut cancers for clinical trial participation. Clin Cancer Res; 23(19); 5687–95. ©2017 AACR.
Outcomes and Complications of Reconstruction with Use of Free Vascularized Fibular Graft for Spinal and Pelvic Defects Following Resection of a Malignant Tumor
Rose, Peter S. , Bakri, Karim , Wagner, Eric R. , Yaszemski, Michael J. , Sim, Franklin H. , Moran, Steven L. , Houdek, Matthew T. , Wagner, Eric R

Mayo Clinic

Journal of Bone and Joint Surgery | July 4, 2017 | Volume: 99 | Issue: 13 | Pages: e69

10.2106/jbjs.16.01458 | PMID 28678130 Get It

Background: Following resection of malignant tumors of the spine and pelvis, reconstructive surgeons often face large structural defects. Unlike reconstruction in the extremities, wherein a free vascularized fibular graft (FVFG) is a highly utilized option for segmental osseous reconstruction, there are limited data on the use of an FVFG in the spine and pelvis. The aim of this study was to review our institution’s experience with reconstruction with use of an FVFG following oncological resection in the spine and pelvis. Methods: We reviewed 24 cases involving the use of an FVFG in reconstruction of segmental osseous defects of the spine and pelvis following oncological resection from 2000 to 2015. The cohort consisted of 12 male and 12 female patients with a mean age of 37 years and a mean follow-up of 5 years. Fifty-four percent of the reconstructions were spinopelvic or sacropelvic. Results: The overall 2, 5, and 10-year rate of survival was 76%, 55%, and 37%, respectively. With regard to disease-free survival, the overall 2, 5, and 10-year rate was 81%, 72%, and 48%. The overall rate of union was 86%, with a mean time to union of 7 months. Complications were common, with 83% of the patients sustaining at least 1 postoperative complication. Following the procedure, the mean Musculoskeletal Tumor Society rating was 53%. Conclusions: An FVFG provides a durable means of reconstruction of osseous defects in the spine and pelvis. Although patient function was acceptable following these large reconstructions, the rate of postoperative complications was high. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Intra‐articular injection of a substance P inhibitor affects gene expression in a joint contracture model
Lewallen, Eric A. , An, Kai‐Nan, Grill, Diane E. , Steinmann, Scott P. , Yao, Jie , Salib, Christopher G. , Trousdale, William H. , Reina, Nicolas , Kremers, Hilal Maradit , Lewallen, David G. , Wijnen, André J. van , Sanchez-Sotelo, Joaquin, Yao, Jie J, Kremers, Hilal M, van Wijnen, Andre J , Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , An, Kai‐Nan , Abdel, Matthew P. , Maradit Kremers, Hilal

Mayo Clinic

Journal of Cellular Biochemistry | July 3, 2017 | Volume: 119 | Issue: 2 | Pages: 1326-1336

10.1002/jcb.26256 | PMID 28671282 Get It

AbstractSubstance P (SP), a neurotransmitter released after injury, has been linked to deregulated tissue repair and fibrosis in musculoskeletal tissues and other organs. Although SP inhibition is an effective treatment for nausea, it has not been previously considered as an anti‐fibrotic therapy. Although there are extensive medical records of individuals who have used SP antagonists, our analysis of human registry data revealed that patients receiving these antagonists and arthroplasty are exceedingly rare, thus precluding a clinical evaluation of their potential effects in the context of arthrofibrosis. Therefore, we pursued in vivo studies to assess the effect of SP inhibition early after injury on pro‐fibrotic gene expression and contractures in an animal model of post‐traumatic joint stiffening. Skeletally mature rabbits (n = 24) underwent surgically induced severe joint contracture, while injected with either fosaprepitant (a selective SP antagonist) or saline (control) early after surgery (3, 6, 12, and 24 h). Biomechanical testing revealed that differences in mean contracture angles between the groups were not statistically significant (P = 0.27), suggesting that the drug neither mitigates nor exacerbates joint contracture. However, microarray gene expression analysis revealed that mRNA levels for proteins related to cell signaling, pro‐angiogenic, pro‐inflammatory, and collagen matrix production were significantly different between control and fosaprepitant treated rabbits (P < 0.05). Hence, our study demonstrates that inhibition of SP alters expression of pro‐fibrotic genes in vivo. This finding will motivate future studies to optimize interventions that target SP to reduce the formation of post‐traumatic joint contractures.